Dr. Kuo-Chen Wei, Vice President of Tucheng Hospital, and his team have developed an innovative automatic nucleic acid production and encapsulation technology. This technology uses biological processes to produce stable nucleic acid carriers, constructing self-assembling virus-like nucleic acid carriers similar to bacteriophages. These carriers can transport functional nucleic acids such as siRNA, miRNA, fluorescent tracking aptamers, or target-specific aptamers. The nucleic acid carriers feature modular multifunctional design, automatic nucleic acid encapsulation, and stable biological processes, allowing for precise regulation of the types of nucleic acids carried and enhancing their stability.
Enhancing Stability and Customization, Overcoming Traditional Technology Limitations
In recent years, the significance of gene therapy in various disease treatments has become increasingly recognized. However, traditional gene nucleic acid carrier production processes often involve synthesis and encapsulation, resulting in products with relatively poor stability and convenience for storage. Furthermore, traditional processes typically can only carry a single gene, limiting their application. This new technology offers several advantages:
-Modular Multifunctional Nucleic Acid Design: The RNA framework in this technology provides multiple functional cores that can be replaced with desired sequences, offering customization benefits. Experiments have confirmed that regardless of the sequence changes, the core functionality is retained without losing effectiveness.
-Automatic Nucleic Acid Encapsulation: Utilizing the interaction between RNA and capsid proteins, this technology ensures that RNA is automatically encapsulated within the protein shell, with fixed proportions of functional RNA. Each nanoparticle contains an even number of RNA frameworks, making dosage control easier. The automatic encapsulation process also reduces yield loss and improves production efficiency.
-Stable Biological Process: From RNA to carriers to finished products, the entire process is completed within the cells. The cells can be cultured in large quantities to increase production capacity, and the same cell line ensures consistency in RNA and protein output. This technology has undergone a 500-liter pilot production test, showing no significant differences compared to laboratory-scale standard products. Thus, the process is simpler and more cost-effective than traditional nucleic acid synthesis.
A New Engine for Nucleic Acid Therapy: Disruptive, Highly Safe, and Promising Market Potential
Dr. Wei states that nucleic acid therapy is poised to become a prominent trend in future medical treatments. Currently in its early stages, there is an urgent need for an effective and rapidly deployable platform to accelerate development and mass production. This technology challenges traditional thinking by integrating RNA frameworks and carriers, significantly enhancing stability and customization. Using a full biological process, the products contain only proteins and nucleic acids, ensuring high safety. They have passed OECD standard tests and animal experiments. The team will continue to refine the technology, anticipating that the future market will encompass upstream sectors of scientific research and medical applications, with a growing market scale.
Resource (mandarin): 顛覆傳統製程！創新核酸封裝技術精準調控核酸種類、快速生產！
